You are here

Article info

Article menu

Download PDFPDF

Immune cell therapies and immune cell engineering
Original research
Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy

Authors

  • Xin Liu Keck School of Medicine, University of Southern California, Los Angeles, California, USACenter for Inflammation and Epigenetics, Houston Methodist Research Institute, Houston, Texas, USAInstitute of Biosciences and Technology, College of Medicine, Texas A&M University, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Yixiang Xu Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Wei Xiong Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Bingnan Yin Keck School of Medicine, University of Southern California, Los Angeles, California, USACenter for Inflammation and Epigenetics, Houston Methodist Research Institute, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Yuqian Huang Center for Inflammation and Epigenetics, Houston Methodist Research Institute, Houston, Texas, USAXiangya School of Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China PubMed articlesGoogle scholar articles
  • Junjun Chu Keck School of Medicine, University of Southern California, Los Angeles, California, USACenter for Inflammation and Epigenetics, Houston Methodist Research Institute, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Changsheng Xing Keck School of Medicine, University of Southern California, Los Angeles, California, USACenter for Inflammation and Epigenetics, Houston Methodist Research Institute, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Chen Qian Keck School of Medicine, University of Southern California, Los Angeles, California, USACenter for Inflammation and Epigenetics, Houston Methodist Research Institute, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Yang Du Keck School of Medicine, University of Southern California, Los Angeles, California, USACenter for Inflammation and Epigenetics, Houston Methodist Research Institute, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Tianhao Duan Keck School of Medicine, University of Southern California, Los Angeles, California, USACenter for Inflammation and Epigenetics, Houston Methodist Research Institute, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Helen Y Wang Keck School of Medicine, University of Southern California, Los Angeles, California, USACenter for Inflammation and Epigenetics, Houston Methodist Research Institute, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Ningyan Zhang Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • John S. Yu Neurosurgical Oncology in the Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, USA PubMed articlesGoogle scholar articles
  • Zhiqiang An Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Rongfu Wang Keck School of Medicine, University of Southern California, Los Angeles, California, USACenter for Inflammation and Epigenetics, Houston Methodist Research Institute, Houston, Texas, USAInstitute of Biosciences and Technology, College of Medicine, Texas A&M University, Houston, Texas, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Zhiqiang An; Zhiqiang.An{at}uth.tmc.edu; Dr Rongfu Wang; rongfuwa{at}usc.edu
View Full Text

Citation

Liu X, Xu Y, Xiong W, et al
Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy
Journal for ImmunoTherapy of Cancer 2022;10:e004035. doi: 10.1136/jitc-2021-004035

Publication history

  • Accepted February 27, 2022
  • First published March 25, 2022.
Online issue publication 
October 18, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.